報價延遲最少15分鐘:2024/06/14 14:03 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.57 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.75/-2.50
|
|
企業價值
569.95M
|
| 資產負債 |
|
每股賬面淨值
6.43
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/14 14:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract. |